These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 9732223)
1. Use of serum tumor markers for the diagnosis and follow-up of breast cancer. Barrenetxea G; Schneider J; Llorente MF Oncology; 1998; 55(5):447-9. PubMed ID: 9732223 [No Abstract] [Full Text] [Related]
2. [Serum concentration of selected neoplasm markers: CA15-3, TPS and CEA in women with diagnosed breast benign disease]. Kochańska-Dziurowicz A; Pasich R; Stanjek A; Gaweł-Szostek V; Jankowski T Ginekol Pol; 2000 Sep; 71(9):1139-43. PubMed ID: 11082991 [TBL] [Abstract][Full Text] [Related]
3. Clinical use of tumor markers in the postoperative management of breast cancer patients: new concepts. Nicolini A; Carpi A; Ferrari P; Anselmi L Int J Biol Markers; 1997; 12(4):181-6. PubMed ID: 9582609 [No Abstract] [Full Text] [Related]
4. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247 [TBL] [Abstract][Full Text] [Related]
5. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer. Findeisen R; Albrecht S; Richter B; Deutschmann K; Distler W Clin Chem Lab Med; 1998 Nov; 36(11):841-6. PubMed ID: 9877089 [TBL] [Abstract][Full Text] [Related]
6. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse. Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J Oncology; 1994; 51(6):491-6. PubMed ID: 7970492 [TBL] [Abstract][Full Text] [Related]
7. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients. Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361 [TBL] [Abstract][Full Text] [Related]
8. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487 [TBL] [Abstract][Full Text] [Related]
9. Correlation of biochemical tumor markers with conventional pathological features in primary breast cancer. Péley G; Bezzegh A; Besznyák I; Doleschall Z; Csuka O; Péter I; Tóth J; Számel I; Schumann B; Ottó S Int J Biol Markers; 1999; 14(1):49-51. PubMed ID: 10367251 [TBL] [Abstract][Full Text] [Related]
10. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221 [TBL] [Abstract][Full Text] [Related]
11. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P Clin Chem; 1996 Apr; 42(4):564-75. PubMed ID: 8605674 [TBL] [Abstract][Full Text] [Related]
12. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer. Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655 [TBL] [Abstract][Full Text] [Related]
13. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer. Sölétormos G; Petersen PH; Dombernowsky P Clin Chem Lab Med; 2000 May; 38(5):453-63. PubMed ID: 10952230 [TBL] [Abstract][Full Text] [Related]
14. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations. Nicolini A; Carpi A; Ferrari P; Pieri L Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486 [TBL] [Abstract][Full Text] [Related]
15. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Vizcarra E; Lluch A; Cibrián R; Jarque F; Alberola V; Belloch V; García-Conde J Breast Cancer Res Treat; 1996; 37(3):209-16. PubMed ID: 8825132 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer. Sliwowska I; Kopczyński Z; Grodecka-Gazdecka S Postepy Hig Med Dosw (Online); 2006; 60():295-9. PubMed ID: 16767053 [TBL] [Abstract][Full Text] [Related]
17. Serum (circulating) tumor markers for breast cancer. Hayes DF Recent Results Cancer Res; 1996; 140():101-13. PubMed ID: 8787054 [TBL] [Abstract][Full Text] [Related]
18. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854 [TBL] [Abstract][Full Text] [Related]
19. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. Bottini A; Berruti A; Tampellini M; Morrica B; Brunelli A; Gnocchi E; Brizzi MP; Aguggini S; Fara E; Alquati P; Dogliotti L Tumour Biol; 1997; 18(5):301-10. PubMed ID: 9276030 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of tumour markers in endometrial cancer. Lo SS; Cheng DK; Ng TY; Wong LC; Ngan HY Tumour Biol; 1997; 18(4):241-9. PubMed ID: 9218009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]